Amgen Inc. (NASDAQ:AMGN) Shares Sold by Wealth Architects LLC

Wealth Architects LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,609 shares of the medical research company’s stock after selling 87 shares during the period. Wealth Architects LLC’s holdings in Amgen were worth $419,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $29,000. Centricity Wealth Management LLC purchased a new stake in shares of Amgen in the 4th quarter valued at $25,000. Synergy Investment Management LLC purchased a new stake in shares of Amgen in the 4th quarter valued at $34,000. Atala Financial Inc purchased a new stake in shares of Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AMGN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, UBS Group restated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $314.04.

Amgen Stock Up 0.3 %

Amgen stock opened at $313.71 on Monday. The stock has a market capitalization of $168.53 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.63 and a beta of 0.53. The stock has a 50 day moving average of $291.82 and a two-hundred day moving average of $299.12. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.